SCHEMBL7143354

SCHEMBL7143354

O=Cc1cc(OCCCc2ccccc2)ccc1OCc1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.44
PTGES O14684 1/20 0.44
ALOX5 P09917 1/20 0.44
PPARG P37231 1/20 0.44
ADRB2 P07550 1/20 0.44
AKR1C3 P42330 1/20 0.44
TACR2 P21452 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7143453 0.93 PTGES (0.49) BCHEPTGESALOX5PPARGADRB2
SCHEMBL7148366 0.90 ALDH1A1 (0.45) KDM4EALDH1A1L3MBTL1PTGESALOX5
SCHEMBL7148350 0.88 PTGES (0.53) PTGESALOX5PPARGADRB2FFAR1
SCHEMBL7150750 0.85 TUBB1 (0.55) L3MBTL1TACR2MEN1KMT2ACYP1A2
SCHEMBL9075908 0.84 MEN1 (0.53) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL3615463 0.82 MAOB (0.58) BCHESMN1; SMN2L3MBTL1ALOX5MEN1
SCHEMBL1119150 0.81 JAK2 (0.57) KDM4ESMN1; SMN2L3MBTL1TACR2MEN1
SCHEMBL7146459 0.81 PTGES (0.57) ALDH1A1HTTSMN1; SMN2PTGESALOX5
SCHEMBL7147738 0.81 ABCB1 (0.49) KDM4EALDH1A1SMN1; SMN2PTGESALOX5
SCHEMBL7149340 0.80 MAOB (0.43) L3MBTL1PTGESALOX5PPARGADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US disclosed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US disclosed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP disclosed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037901-A1 Thiazolidinecarboxyl acids TPMT, NAT1, THRA BCHE 4644/4885KDM4E 4209/4885ALDH1A1 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.